Key Points
- Immunome director Isaac Barchas sold 15,248 shares for approximately $397,363 at an average price of $26.06, reducing his direct holdings by 17.39% to 72,416 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- The sale follows several earlier dispositions by Barchas since late June, totaling hundreds of thousands of additional shares and millions of dollars in proceeds.
- Immunome shares were trading near $25.69, while analysts maintained a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $34.18.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Isaac Barchas sold 15,248 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $26.06, for a total value of $397,362.88. Following the sale, the director directly owned 72,416 shares in the company, valued at $1,887,160.96. This trade represents a 17.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Isaac Barchas also recently made the following trade(s):
- On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $543,090.40.
- On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
- On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
- On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
- On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.
Immunome Trading Up 2.6%
Shares of Immunome stock opened at $25.69 on Tuesday. The company has a fifty day simple moving average of $21.59 and a 200-day simple moving average of $22.17. Immunome, Inc. has a 12-month low of $8.66 and a 12-month high of $27.65. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -10.79 and a beta of 2.07.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.12. On average, analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on IMNM shares. Truist Financial upped their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, May 28th. Barclays started coverage on Immunome in a report on Thursday, May 28th. They issued an "overweight" rating and a $36.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a research report on Friday, July 17th. Leerink Partners dropped their price target on Immunome from $37.00 to $33.00 and set an "outperform" rating on the stock in a research note on Friday, May 15th. Finally, Wall Street Zen downgraded Immunome from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Immunome currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.18.
Check Out Our Latest Research Report on IMNM
Hedge Funds Weigh In On Immunome
Several institutional investors have recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. increased its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company's stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. BlackRock Inc. purchased a new position in shares of Immunome in the 2nd quarter valued at approximately $186,588,000. Vanguard Group Inc. grew its stake in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company's stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company's stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company's stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
